https://charts.traderzeitung.de/phases/CA74346M5054 string(1409) "{"isin":"CA74346M5054","name":"ProMIS Neurosciences Inc","stock_id_xnas":132475763,"stock_id_xnys":132475764,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.42,"close_at":"2026-09-21 19:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.79,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":2.7571},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":13.06,"close_at":"2026-09-23 21:15:00","complete":true,"perf_pct":-5.2937},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

ProMIS Neurosciences Aktie News & Nachrichten

[WKN: A41MFQ | Symbol: PMN]

Realtimekurs

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über ProMIS Neurosciences gefunden werden.

ProMIS Neurosciences Nachrichtenticker öffnen

MT Newswires 28.07.2026 16:47 Uhr

ProMIS Neurosciences Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Chardan passt Kursziel für ProMIS Neurosciences von 20 $ auf 33 $ an, belässt Buy-Rating

ProMIS Neurosciences gibt positive Zwischensicherheits- und Biomarkerdaten für Alzheimer-Medikament PMN310 bekannt

Chardan nimmt ProMIS Neurosciences mit Buy und einem Kursziel von 20 USD auf

ProMIS Neurosciences sagt, PMN310 reduzierte Amyloid-Beta-Oligomere in einer Phase-1a-Studie

Cantor Fitzgerald nimmt die Coverage für ProMIS Neurosciences mit 'Übergewichten' auf